Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 10/20 | 0.68 |
| ▸ | CDK7 | P50613 | 8/20 | 0.68 |
| ▸ | ITK | Q08881 | 4/20 | 0.54 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 1/20 | 0.42 |
| ▸ | GSK3B | P49841 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.42 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.42 |
| ▸ | MARK2 | Q7KZI7 | 1/20 | 0.42 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.42 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.42 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.42 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.42 |
| ▸ | SGK2 | Q9HBY8 | 1/20 | 0.42 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.42 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.42 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5055574 | 0.90 | ITK (0.56) | CHEK1CDK7ITKDRD2DRD4 | |
| SCHEMBL5053994 | 0.89 | CHEK1 (0.57) | CHEK1CDK7ITKCLK4LRRK2 | |
| SCHEMBL5061262 | 0.87 | CHEK1 (0.58) | CHEK1CDK7ITKCDK2DRD2 | |
| SCHEMBL27708371 | 0.87 | ITK (0.53) | CHEK1CDK7ITKDRD2DRD4 | |
| SCHEMBL5054046 | 0.87 | CHEK1 (0.56) | CHEK1CDK7ITKDRD2DRD4 | |
| SCHEMBL5054163 | 0.87 | ITK (0.53) | CHEK1CDK7ITKCDK2DRD2 | |
| SCHEMBL5058960 | 0.85 | CHEK1 (0.52) | CHEK1CDK7ITKDRD2DRD4 | |
| SCHEMBL5054096 | 0.85 | CHEK1 (0.70) | CHEK1CDK7ITK | |
| SCHEMBL4161043 | 0.85 | CHEK1 (0.70) | CHEK1CDK7ITKCDK2DRD2 | |
| SCHEMBL5054068 | 0.84 | ITK (0.52) | CHEK1CDK7ITKCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101115724-A | Inhibitors of checkpoint kinases | MERCK & CO INC (US) | 2008-01-30 | — | — | CN | claimed |
| US-20080004259-A1 | Inhibitors of Checkpoint Kinases | MERCK & CO., INC. | 2008-01-03 | — | — | US | claimed |
| EP-1851203-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2007-11-07 | — | — | EP | claimed |
| WO-2006086255-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-08-17 | — | — | WO | claimed |
| CN-101115724-A | Inhibitors of checkpoint kinases | MERCK & CO INC (US) | 2008-01-30 | — | — | CN | disclosed |
| US-20080004259-A1 | Inhibitors of Checkpoint Kinases | MERCK & CO., INC. | 2008-01-03 | — | — | US | disclosed |
| EP-1851203-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006086255-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004259-A1 | Inhibitors of Checkpoint Kinases | CHEK1, CHEK2, BUB1B | CHEK1 1/4885CDK7 43/4885ITK 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.